Valuation of the anti-virus platformThe canadian government
will proceed with fundings once the PHAC animal tests model are completed and successful, following the CRA (Collaborative Research Agreement with UofManitoba and High Containment Respiratory Virus Group, Special Pathogens, PHAC).
It is the PHAC that takes control of the tests, given their unique equipments and expertise as this is the only Level 4 lab in Canada. Level 4 labs are the world's most secure facilities.
PHAC's Dr. Kobasa didn't use the "
development of a Canadian-made COVID-19 vaccine" wording lightly. It is because they will move forward with TLT's vaccine.
For many obvious reasons, governments move forward when they have something of value in their courtyard, as it helps establish the credibility of their country in such field of expertise, helps create jobs, etc ... Same principles as Ontario Health Minister invests in UHN, Princess Margaret Cancer Center, etc ...
The Ebola vaccine was developed at PHAC. The canadian government provided grants to Medicago and other canadian technologies in the COVID-19 field, whenever a window of opportunity was there. So it will with TLT's COVID-19 vaccine if final tests are successful. There's absolutely no doubt.
February 7, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds1 (“PDC”) and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (“COVID-19”) vaccine. Theralase® is pleased to be able to report today that PHAC has demonstrated that light-activated TLD-1433, was effective in rapidly inactivating the SARS-CoV-2 virus by up to 99.99%, compared to control in an in vitro study. Further research is required to confirm these findings.
These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
Darwyn Kobasa, Ph.D., Head, High Containment Respiratory Virus Group, Special Pathogens, PHAC, stated “My team’s initial results indicate that, when activated by light, TLD-1433 is very effective in inactivating the COVID-19 virus at low concentrations, thus demonstrating proof-of-concept in the development of a Canadian-made COVID-19 vaccine.”
Kevin Coombs, Ph.D., Professor, Department of Medical Microbiology at UM, stated, “The work conducted at my lab and the work conducted by PHAC’s National Microbiology Laboratory, has demonstrated that a large range of enveloped viruses can be successfully inactivated by light-activated TLD-1433 at low concentrations. I am delighted that Theralase®’s and my initial preclinical research has proven to be effective in COVID-19.
Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, “The latest preliminary results by Dr. Kobasa and Dr. Coombs, demonstrates that the Theralase® vaccine may potentially be effective as a Canadian-made wholly-inactivated vaccine to prevent individuals from contracting COVID-19 in the future and warrants further research to confirm the findings. The research also demonstrates that the Theralase® platform is extremely versatile, with an ability to be applicable to a wide range of enveloped viruses. This would allow the Company to tailor the vaccine to be potentially effective against contracting various viruses (existing and/or new) and their associated variants. Based on this encouraging data, the Company intends to move forward in the research, development and commercialization of the Theralase® COVID-19 vaccine, subject to the required regulatory approval.”
Valuation of an anti-virus platform, considering this:
- we have proof-of-concept data conducted by PHAC’s National Microbiology Laboratory regarding the destruction of viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations. These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus. _______________________
livermore2 - (9/13/2021 7:58:01 PM)
Who saw the news on Providence Therapeutics today
Sold COVID vaccine license for estimated 500MM$ deal - 100MM$ cash up front!!! More on that deal, to be able to provide a potential valuation to TLT's anti-virus platform:
Sept. 13, 2021:
- Providence and Everest enter into a 50/50 worldwide collaboration to jointly develop products in two additional indications, leveraging Providence’s cutting-edge mRNA technology
- Providence will receive 100M$US upfront, up to 12% equity position in Everest based upon milestones, and future profit share and royalties
Transaction Terms
Under the terms of the transaction Agreements, Providence will receive the following considerations;
For COVID-19 vaccines:
• US$50 million in initial upfront payment to be paid in cash;
• In China and Singapore, up to US$100 million in profit-sharing on COVID-19 vaccines, and once profit share has reached an aggregate amount of US$100 million, mid to high single-digit royalties, and in Everest Territories outside of China and Singapore, mid-teens royalties on COVID-19 vaccine sales.
For Collaboration Products, Additional Products, and the mRNA technology platform:
• US$50 million in initial upfront payment to be paid in cash;
• Up to US$300 million in future milestone payments to be paid in newly-issued Everest stock, based on the achievement of certain technology transfer, manufacturing, preclinical, development and commercial milestones.
Sept. 14, 2021
Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B - Providence Therapeutics The biotech has received some funding from the Canadian government as well as upfront payments from its Indian partner Biological E Limited. and Chinese partner Everest Medicines Limited. It now plans to seek a further $400m in funding, CEO Brad Sorenson tells Scrip in this audio interview.
Along with Biological E and its North American partners - Emergent BioSolutions, Inc. and Northern Therapeutics Inc.- Providence aims to produce 1-1.5 billion doses of its coronavirus vaccines.
In the interview, Sorenson also discusses vaccines against cancer that are part of Providence Therapeutics’ suite of mRNA products.